M&T Bank Corp Maxcyte, Inc. Transaction History

M&T Bank Corp

$231 Billion
Q4 2024

A detailed history of M&T Bank Corp transactions in Maxcyte, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 113,882 shares of MXCT stock, worth $390,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares

113,882

Previous 113,778 0.09%

Holding current value

$390,615

Previous $442,000 7.01%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$3.23 - $4.43 $335 - $460	104 Added 0.09%	113,882 $473,000
Q3 2024 Nov 15, 2024	BUY	$3.68 - $5.06 $94,369 - $129,758	25,644 Added 29.1%	113,778 $442,000
Q2 2024 Jul 31, 2024	BUY	$3.63 - $5.0 $290 - $400	80 Added 0.09%	88,134 $345,000
Q1 2024 May 07, 2024	BUY	$3.94 - $5.38 $717 - $979	182 Added 0.21%	88,054 $368,000
Q4 2023 Feb 06, 2024	SELL	$2.6 - $5.24 $196,666 - $396,358	-75,641 Reduced 46.26%	87,872 $412,000
Q3 2023 Nov 02, 2023	BUY	$3.02 - $5.1 $16,437 - $27,759	5,443 Added 3.44%	163,513 $510,000
Q2 2023 Aug 09, 2023	BUY	$3.69 - $5.35 $122,257 - $177,256	33,132 Added 26.52%	158,070 $725,000
Q4 2022 Feb 13, 2023	SELL	$4.92 - $7.4 $210,659 - $316,845	-42,817 Reduced 40.54%	62,809 $342,000
Q4 2022 Feb 13, 2023	BUY	$4.92 - $7.4 $305,674 - $459,754	62,129 Added 98.92%	124,938 $682,000
Q2 2022 Aug 05, 2022	BUY	$3.59 - $6.81 $379,197 - $719,313	105,626 New	105,626 $500,000
Q1 2022 May 09, 2022	SELL	$5.26 - $10.84 $130,142 - $268,203	-24,742 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$8.87 - $12.94 $11,974 - $17,469	1,350 Added 5.77%	24,742 $252,000
Q3 2021 Oct 28, 2021	BUY	$12.21 - $17.2 $285,616 - $402,342	23,392 New	23,392 $286,000

Others Institutions Holding MXCT

# of Institutions

123

Shares Held

69.8M

Call Options Held

8.7K

Put Options Held

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $349M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account